Literature DB >> 18755983

Long-term increases in lymphocytes and platelets in human T-lymphotropic virus type II infection.

Melissa T Bartman1, Zhanna Kaidarova, Dale Hirschkorn, Ronald A Sacher, Joy Fridey, George Garratty, Joan Gibble, James W Smith, Bruce Newman, Anthony E Yeo, Edward L Murphy.   

Abstract

Human T-lymphotropic viruses types I and II (HTLV-I and HTLV-II) cause chronic infections of T lymphocytes that may lead to leukemia and myelopathy. However, their long-term effects on blood counts and hematopoiesis are poorly understood. We followed 151 HTLV-I-seropositive, 387 HTLV-II-seropositive, and 799 HTLV-seronegative former blood donors from 5 U.S. blood centers for a median of 14.0 years. Complete blood counts were performed every 2 years. Multivariable repeated measures analyses were conducted to evaluate the independent effect of HTLV infection and potential confounders on 9 hematologic measurements. Participants with HTLV-II had significant (P < .05) increases in their adjusted lymphocyte counts (+126 cells/mm(3); approximately +7%), hemoglobin (+2 g/L [+0.2 g/dL]) and mean corpuscular volume (MCV; 1.0 fL) compared with seronegative participants. Participants with HTLV-I and HTLV-II had higher adjusted platelet counts (+16 544 and +21 657 cells/mm(3); P < .05) than seronegatives. Among all participants, time led to decreases in platelet count and lymphocyte counts, and to increases in MCV and monocytes. Sex, race, smoking, and alcohol consumption all had significant effects on blood counts. The HTLV-II effect on lymphocytes is novel and may be related to viral transactivation or immune response. HTLV-I and HTLV-II associations with higher platelet counts suggest viral effects on hematopoietic growth factors or cytokines.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18755983      PMCID: PMC2581993          DOI: 10.1182/blood-2008-05-155960

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  50 in total

Review 1.  Molecular pathogenesis of anemia of chronic disease.

Authors:  Tomas Ganz
Journal:  Pediatr Blood Cancer       Date:  2006-05-01       Impact factor: 3.167

2.  Haplotypes of IL6 and IL10 and susceptibility to human T lymphotropic virus type I infection among children.

Authors:  Elizabeth E Brown; Brandon J Brown; Meredith Yeager; Robert Welch; Beverly Cranston; Barrie Hanchard; Michie Hisada
Journal:  J Infect Dis       Date:  2006-10-18       Impact factor: 5.226

3.  Long-term variations in human T lymphotropic virus (HTLV)-I and HTLV-II proviral loads and association with clinical data.

Authors:  Nicholas Kwaan; Tzong-Hae Lee; Daniel M Chafets; Catharie Nass; Bruce Newman; James Smith; George Garratty; Edward L Murphy
Journal:  J Infect Dis       Date:  2006-10-27       Impact factor: 5.226

4.  Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease.

Authors:  M Yoshida; I Miyoshi; Y Hinuma
Journal:  Proc Natl Acad Sci U S A       Date:  1982-03       Impact factor: 11.205

5.  In vivo T lymphocyte dynamics in humans and the impact of human T-lymphotropic virus 1 infection.

Authors:  Becca Asquith; Yan Zhang; Angelina J Mosley; Catherine M de Lara; Diana L Wallace; Andrew Worth; Lambrini Kaftantzi; Kiran Meekings; George E Griffin; Yuetsu Tanaka; David F Tough; Peter C Beverley; Graham P Taylor; Derek C Macallan; Charles R M Bangham
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-01       Impact factor: 11.205

6.  Thrombopoietin, but not cytokines binding to gp130 protein-coupled receptors, activates MAPKp42/44, AKT, and STAT proteins in normal human CD34+ cells, megakaryocytes, and platelets.

Authors:  Marcin Majka; Janina Ratajczak; Gaston Villaire; Krystyna Kubiczek; Leah A Marquez; Anna Janowska-Wieczorek; Mariusz Z Ratajczak
Journal:  Exp Hematol       Date:  2002-07       Impact factor: 3.084

7.  Transcriptional regulation of the human interleukin-6 gene promoter in human T-cell leukemia virus type I-infected T-cell lines: evidence for the involvement of NF-kappa B.

Authors:  N Mori; F Shirakawa; H Shimizu; S Murakami; S Oda; K Yamamoto; S Eto
Journal:  Blood       Date:  1994-11-01       Impact factor: 22.113

Review 8.  Anemia in the elderly: current understanding and emerging concepts.

Authors:  Richard Eisenstaedt; Brenda W J H Penninx; Richard C Woodman
Journal:  Blood Rev       Date:  2006-02-10       Impact factor: 8.250

Review 9.  Chronic myelopathy associated with human T-lymphotropic virus type I (HTLV-I).

Authors:  A Gessain; O Gout
Journal:  Ann Intern Med       Date:  1992-12-01       Impact factor: 25.391

10.  Respiratory and urinary tract infections, arthritis, and asthma associated with HTLV-I and HTLV-II infection.

Authors:  Edward L Murphy; Baoguang Wang; Ronald A Sacher; Joy Fridey; James W Smith; Catharie C Nass; Bruce Newman; Helen E Ownby; George Garratty; Shelia T Hutching; George B Schreiber
Journal:  Emerg Infect Dis       Date:  2004-01       Impact factor: 6.883

View more
  35 in total

1.  HTLV-2 APH-2 expression is correlated with proviral load but APH-2 does not promote lymphocytosis.

Authors:  Estelle Douceron; Zhanna Kaidarova; Paola Miyazato; Masao Matsuoka; Edward L Murphy; Renaud Mahieux
Journal:  J Infect Dis       Date:  2011-11-07       Impact factor: 5.226

2.  Increased all-cause and cancer mortality in HTLV-II infection.

Authors:  Hope H Biswas; Zhanna Kaidarova; George Garratty; Joan W Gibble; Bruce H Newman; James W Smith; Alyssa Ziman; Joy L Fridey; Ronald A Sacher; Edward L Murphy
Journal:  J Acquir Immune Defic Syndr       Date:  2010-07       Impact factor: 3.731

3.  Distinct transformation tropism exhibited by human T lymphotropic virus type 1 (HTLV-1) and HTLV-2 is the result of postinfection T cell clonal expansion.

Authors:  Priya Kannian; Han Yin; Rami Doueiri; Michael D Lairmore; Soledad Fernandez; Patrick L Green
Journal:  J Virol       Date:  2012-01-25       Impact factor: 5.103

4.  Human T-cell leukemia virus type 2 antisense viral protein 2 is dispensable for in vitro immortalization but functions to repress early virus replication in vivo.

Authors:  Han Yin; Priya Kannian; Nathan Dissinger; Robyn Haines; Stefan Niewiesk; Patrick L Green
Journal:  J Virol       Date:  2012-05-23       Impact factor: 5.103

5.  Human T cell leukaemia virus type 2 tax protein mediates CC-chemokine expression in peripheral blood mononuclear cells via the nuclear factor kappa B canonical pathway.

Authors:  C S Barrios; L Castillo; H Zhi; C-Z Giam; M A Beilke
Journal:  Clin Exp Immunol       Date:  2014-01       Impact factor: 4.330

6.  Recombinant human T-cell leukemia virus types 1 and 2 Tax proteins induce high levels of CC-chemokines and downregulate CCR5 in human peripheral blood mononuclear cells.

Authors:  Christy S Barrios; Muna Abuerreish; Michael D Lairmore; Laura Castillo; Chou-Zen Giam; Mark A Beilke
Journal:  Viral Immunol       Date:  2011-11-23       Impact factor: 2.257

7.  The ESCRT-0 Protein HRS Interacts with the Human T Cell Leukemia Virus Type 2 Antisense Protein APH-2 and Suppresses Viral Replication.

Authors:  Fanny Martini; Coline Arone; Amy Hasset; William W Hall; Noreen Sheehy
Journal:  J Virol       Date:  2019-12-12       Impact factor: 5.103

8.  Human T-cell leukemia virus type 2 produces a spliced antisense transcript encoding a protein that lacks a classic bZIP domain but still inhibits Tax2-mediated transcription.

Authors:  Marilène Halin; Estelle Douceron; Isabelle Clerc; Chloé Journo; Nga Ling Ko; Sébastien Landry; Edward L Murphy; Antoine Gessain; Isabelle Lemasson; Jean-Michel Mesnard; Benoît Barbeau; Renaud Mahieux
Journal:  Blood       Date:  2009-07-14       Impact factor: 22.113

9.  One-step, multiplex, real-time PCR assay with molecular beacon probes for simultaneous detection, differentiation, and quantification of human T-cell leukemia virus types 1, 2, and 3.

Authors:  Guillaume Besson; Mirdad Kazanji
Journal:  J Clin Microbiol       Date:  2009-02-11       Impact factor: 5.948

10.  Preexisting infection with human T-cell lymphotropic virus type 2 neither exacerbates nor attenuates simian immunodeficiency virus SIVmac251 infection in macaques.

Authors:  Shari N Gordon; Anna R Weissman; Valentina Cecchinato; Claudio Fenizia; Zhong-Min Ma; Tzong-Hae Lee; Lorenzo Zaffiri; Vibeke Andresen; Robyn Washington Parks; Kathryn S Jones; Jean Michel Heraud; Maria Grazia Ferrari; Hye Kyung Chung; David Venzon; Renaud Mahieux; Edward L Murphy; Steven Jacobson; Christopher J Miller; Francis W Ruscetti; Genoveffa Franchini
Journal:  J Virol       Date:  2010-01-13       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.